Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high ...

The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...

Black race, regardless of cytogenetics, was found to be associated with poorer survival in a 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) ...

A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...

Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates. With a median ...

The triplet regimen of azacitidine, venetoclax, and tagraxofusp showed high complete response rates in both untreated and relapsed/refractory BPDCN patients. Safety profile of the triplet was ...

The KOMET-007 trial demonstrated that ziftomenib combined with venetoclax and azacitidine was well-tolerated in relapsed/refractory AML patients with NPM1 mutations or KMT2A rearrangements. Common ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

The SAVE regimen achieved an 86% ORR in newly diagnosed AML, with high MRD-negative rates, especially in NPM1 mutations or KMT2A rearrangements. Significant myelosuppression and infectious ...

MaaT013 showed a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits for responders. Safety profile was acceptable, with ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...